ArticleNPJ Parkinson's disease2026
Plasma ceramide ratios define metabolic-inflammatory associations with cognitive impairment in Parkinson's disease.
Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Cognitive impairment in Parkinson's disease (PD) remains difficult to stratify using accessible fluid biomarkers, and the metabolic-inflammatory relationships associated with cognitive decline remain incompletely quantified. Here, we examined the relationships among plasma ceramides, inflammatory cytokines, neurodegeneration biomarkers, and cognitive function in PD patients with varying degrees of cognitive impairment, patients with multiple system atrophy (MSA), and healthy controls. MSA was distinguished from PD by higher Cer 18:0/Cer 24:0 and Cer 24:1/Cer 24:0 ratios, despite overlapping cytokine and neurofilament light chain (NFL) profiles. Within PD, worsening cognitive status was accompanied by graded increases in specific ceramide ratios, inflammatory cytokines, and NFL. Cer 24:1/Cer 24:0 was independently associated with cognitive performance (B = - 2.01, P = 0.003). Structural equation modeling identified two association pathways between ceramide-related measures and cognition: a larger direct association (standardized β = -0.223; 60.8% of the total effect) and a smaller inflammation-related indirect association (standardized β = -0.133; 36.2%), whereas pathways involving NFL were not significant. These findings establish a ceramide-centered quantitative framework integrating metabolic and inflammatory dimensions of cognitive impairment in PD, supporting stratified biomarker development.
Identifiers
42463685What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.